Vaccine Adjuvants
We at SPI are actively expanding our influence in the vaccine adjuvants field. Our strategic growth includes executing significant expansion in the vaccine adjuvant technology market and making substantial investments to enhance our capabilities.
SPI Pharma partners with Q-Vant Biosciences and Inimmune to strengthen our leadership in vaccine adjuvant solutions. With Q-Vant’s sustainable saponin extraction technology and Inimmune’s expertise in novel small molecule adjuvants and delivery systems, we combine innovation, quality, and global reach to provide scalable, high-purity, and next-generation adjuvant solutions for the pharmaceutical industry.
Available Products
Adjuvant Systems
SPI Pharma and Inimmune, have created a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. The collaboration leverages Inimmune's world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma's extensive manufacturing and global commercial capabilities.
Saponin Based Adjuvants
Quillaja saponin-based adjuvants like QS-21 are powerful tools for boosting vaccine effectiveness but rely on non-sustainable sources, posing supply risks. Efforts are underway to develop a more sustainable solution.
High Adsorption Alum Adjuvants
The vaccine adjuvant manufacturing process has been optimized to create an adjuvant with a higher protein adsorption capacity, a finer particle size and a narrower pH range. These characteristics make VAC 20 HA a high-performance adjuvant compared to other regular adjuvants.
Alum Vaccine Adjuvants
SPI Pharma offers a range of aluminum hydroxide gel VAC grades for adsorption (pseudo-boehmite form) for use as a vaccine adjuvant. It is used to bind negatively charged antigens.